AI assistant
BIOGEN INC. — Director's Dealing 2022
Aug 31, 2022
30291_dirs_2022-08-31_55f13180-8c0a-45fe-9a8f-967451f42f1c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SANGAMO THERAPEUTICS, INC (SGMO)
CIK: 0001001233
Period of Report: 2022-08-29
Reporting Person: BIOGEN INC. (10% Owner)
Reporting Person: Biogen MA Inc. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-08-29 | Common Stock | S | 400000 | $5.3268 | Disposed | 23752466 | Indirect |
| 2022-08-30 | Common Stock | S | 100000 | $5.2652 | Disposed | 23652466 | Indirect |
Footnotes
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.205 to $5.475, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Shares are owned indirectly by Biogen Inc. and directly by its wholly-owned subsidiary Biogen MA Inc.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1235 to $5.49, inclusive. The reporting person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.